AXSM — Axsome Therapeutics Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $135.95
- YTD price return
- -25.56%
- YTD total return
- -25.56%
- Market cap
- 7.2B
- Enterprise value
- 7.1B
- Shares outstanding
- 52.6M
- 52W low
- $123.00
- 52W high
- $260.19
- From 52W high
- -47.75%
- From 52W low
- +10.53%
- 52W range
- 9%$123–$260
- Beta
- 0.72
Volume
- Rel volume
- 0.49×
- 30D volume
- 1.1M
- 30D $ vol
- 155.8M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$2.1M
- Insider net 1Y
- −$100.9M
Form 4 transactions by trade date, as filed; latest on file 2026-09-03.
Fundamentals
- Sales (ttm)
- 865.3M
- Sales/share
- $16.45
- EPS (ttm)
- -$3.05
- FCF (ttm)
- -82.6M
- FCF/share
- -$1.57
- Book value/share
- $2.00
- Net margin
- -18.18%
- ROE
- -149.19%
- ROA
- -19.02%
- Debt / equity
- 1.12×
- Current ratio
- 1.42
Growth (CAGR, ttm) · 10Y
- Sales
- +54.21%+57.02%n/an/a
- Shares
- +4.34%+3.59%+6.89%+10.63%
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +47.79%+51.58%n/an/a
- Book value/share
- +37.09%-29.39%+12.08%+3.14%
- Price
- -6.61%+31.42%+31.52%+33.87%
- Total return
- -6.61%+31.42%+31.52%+33.87%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -44.5×
- Fwd P/E
- 41.9×
- P/S (ttm)
- 8.3×
- P/B (mrq)
- 67.8×
- EV/Sales (ttm)
- 8.2×
- FCF yield (ttm)
- -1.16%
- Buyback yield (realized, 1y)
- -4.34%
- Shareholder yield (realized, 1y)
- -4.34%
- Buyback yield (cash, ttm)
- -0.36%
- Shareholder yield (cash, ttm)
- -0.36%
Vs own 10Y history
- P/S
- 0th
- P/B
- 67th
Bar = where today’s multiple sits in AXSM’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m10Y n/mYoY n/mEPS (diluted)
5Y n/m5Y n/mYoY n/mFree cash flow
5Y n/m10Y n/mYoY n/mTTM: operating cash flow −$81.8M, capex −$839K
Q3 2026: operating cash flow −$9.5M, capex −$197K
Shares (diluted)
5Y +33.7%5Y +33.7%YoY +4.8%Net income
5Y n/m10Y n/mYoY n/mAbout Axsome Therapeutics#
Data provided bySource: Twelve DataAxsome Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders. Its marketed products include Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness related to narcolepsy or obstructive sleep apnea, and Symbravo for the acute treatment of migraine. The company also maintains a neuroscience pipeline spanning additional neurological and psychiatric conditions, reflecting its emphasis on disorders with limited treatment options. Axsome Therapeutics Inc. plays a specialized role in the healthcare market by combining commercial products with ongoing clinical development in psychiatry, sleep medicine, pain, and migraine care. Based in New York, the company is positioned as a focused CNS innovator serving patients, physicians, and healthcare systems with therapies designed to address unmet medical needs.
New York, NY·1,346 employees·Biotechnology·axsome.com·As of Oct 28, 2026
Recent filings#
- Nov 2Earnings · Earnings release — EPS −$0.25 vs −$0.69 est. (+63.8%); revenue $259.7M (+52% y/y) 5.8%
- Aug 10Earnings · Earnings release — EPS −$0.99 vs −$0.99 est. (+0.0%); revenue $218.4M (+46% y/y) 3.8%
ETFs holding AXSM#
18 of the 193 ETFs ChartRow carries live hold AXSM. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 0.8% |
| VBK | Vanguard Small-Cap Growth ETF | 0.3% |
| IWP | iShares Russell Mid-Cap Growth ETF | 0.3% |
| VB | Vanguard Small-Cap ETF | 0.1% |
| VXF | Vanguard Extended Market ETF | 0.1% |
| VHT | Vanguard Health Care ETF | 0.1% |
| IWR | iShares Russell Midcap ETF | 0.1% |
| IWF | iShares Russell 1000 Growth ETF | 0.0% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
